From: Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease
First author | Phase year | Disease | Treatment | Subject(n) treatment/control | Findings | Ref |
---|---|---|---|---|---|---|
Stewart, Duncan J | Phase II 2008 | CHD | Intramyocardial VEGF plasmid | 48/45 | No therapeutic effect | [37] |
Richard J Powell | Phase II 2010 | CLI | Intramuscular HGF plasmid | 21/6 | Improved ABI, no change in wound healing, major amputation, or death | [38] |
Jill Belch | Phase III 2011 | CLI | Intramuscular FGF plasmid | 259/266 | Failed to reduce amputation or death | [39] |
Motoyuki Kumagai | Phase I/IIa 2016 | CLI | Intramuscular FGF plasmid incorporated with gelatin hydrogel microspheres | 10/0 | Provided a safe and effective form of angiogenesis | [40] |
Deev, R | Phase IIb/III 2018 | CLI | Intramuscular VEGF165 plasmid | 36/12 | Improved ABI, TcPO2 and PWD | [41] |
Gu, Y | Phase II 2019 | CLI | Intramuscular HGF plasmid | 150/50 | Completed pain relief and improved the healing of ulcers | [42] |
Barć, P | Phase II 2021 | CLI | Intramuscular pIRES/VEGF165/HGF | 14/14 | Increased ABI and vascularization, decreased rest pain | [43] |